List of Gene Editing/CRISPR Companies in Austria - 2

a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement. The technology has been pioneered by the company’s co-founders Madeline Lancaster and Juergen Knoblich and is exclusively licensed to a:head by the Institute of Molecular Biotechnology, Vienna, Austria. a:head applies these complex 3D tissue cultures for modelling of various brain disorders in a human context and aims at translating the technology into a powerful high content, high throughput phenotyping platform for the development of novel CNS therapeutics.

Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens. Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions (MoA) of drugs. Each screening project is customized to the specific needs of our clients and we perturb cells with CRISPR KO, CRISPR interference or CRISPR activation coupled to high-content read-outs such as fitness, FACS and single-cell transcriptomics. Notably, we offer single-cell CRISPR screens (CROP-Seq) in cancer cells and primary immune cells, including primary human T cells to support biotech and pharma companies striving to develop novel CAR-T and TCR-T cell therapeutics.